相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin
Bibian M. E. Tullemans et al.
THROMBOSIS AND HAEMOSTASIS (2022)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Epidemiology of Renal Cell Carcinoma
Sandeep Anand Padala et al.
WORLD JOURNAL OF ONCOLOGY (2020)
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction
Joi Ninomoto et al.
HEMATOLOGY (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
New Insights Into the Differentiation of Megakaryocytes From Hematopoietic Progenitors
Leila J. Noetzli et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST)
D. Den Hollander et al.
ACTA ONCOLOGICA (2019)
Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
Maudy Walraven et al.
ANGIOGENESIS (2018)
Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy
Constance C. F. M. J. Baaten et al.
HAEMATOLOGICA (2018)
Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors
B. M. E. Tullemans et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy
Constance C. F. M. J. Baaten et al.
HAEMATOLOGICA (2018)
Effects of atorvastatin on ADP-, arachidonic acid-, collagen-, and epinephrine-induced platelet aggregation
Lei Zhao et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2017)
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study CALGB 30607 (Alliance)
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma
Juhana Rautiola et al.
BJU INTERNATIONAL (2016)
Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
Zachary Hamilton et al.
BJU INTERNATIONAL (2016)
Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Marie Levade et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Sunitinib uptake inhibits platelet function in cancer patients
Siamack Sabrkhany et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Targeting cancer with kinase inhibitors
Stefan Gross et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion
Richard J. Lin et al.
BLOOD (2014)
Platelet-Cancer Interactions
Hadi A. Goubran et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2014)
Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care
Nienke A. G. Lankheet et al.
THERAPEUTIC DRUG MONITORING (2014)
NEW FUNDAMENTALS IN HEMOSTASIS
Henri H. Versteeg et al.
PHYSIOLOGICAL REVIEWS (2013)
Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
Steven M. Bair et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2013)
Atorvastatin Delays Murine Platelet Activation In Vivo Even in the Absence of Endothelial NO Synthase
Ran Ni et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation
Alexandra Mazharian et al.
BLOOD (2011)
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy
Timothy D. Warner et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
R. Honeywell et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2010)
Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule
Astrid A. M. van der Veldt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib
Doru T. Alexandrescu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Platelets take up the monoclonal antibody bevacizumab
Henk M. W. Verheu et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
Val R. Adams et al.
CLINICAL THERAPEUTICS (2007)
Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding
SJ Stanworth et al.
VOX SANGUINIS (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation -: A study with healthy subjects and patients at thrombotic risk
PEJ van der Meijden et al.
THROMBOSIS AND HAEMOSTASIS (2005)
Relationship between platelet count and bleeding risk in thrombocytopenic patients
SJ Slichter
TRANSFUSION MEDICINE REVIEWS (2004)
分享论文
